AU2012253652B2 - Genetically engineered growth factor variants - Google Patents

Genetically engineered growth factor variants Download PDF

Info

Publication number
AU2012253652B2
AU2012253652B2 AU2012253652A AU2012253652A AU2012253652B2 AU 2012253652 B2 AU2012253652 B2 AU 2012253652B2 AU 2012253652 A AU2012253652 A AU 2012253652A AU 2012253652 A AU2012253652 A AU 2012253652A AU 2012253652 B2 AU2012253652 B2 AU 2012253652B2
Authority
AU
Australia
Prior art keywords
protein
cell
noc
dimer
igg2ah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012253652A
Other languages
English (en)
Other versions
AU2012253652A1 (en
Inventor
Cynthia Bamdad
Benoit J. Smagghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of AU2012253652A1 publication Critical patent/AU2012253652A1/en
Application granted granted Critical
Publication of AU2012253652B2 publication Critical patent/AU2012253652B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
AU2012253652A 2011-05-09 2012-05-08 Genetically engineered growth factor variants Active AU2012253652B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Publications (2)

Publication Number Publication Date
AU2012253652A1 AU2012253652A1 (en) 2013-11-28
AU2012253652B2 true AU2012253652B2 (en) 2017-07-06

Family

ID=47139949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012253652A Active AU2012253652B2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Country Status (8)

Country Link
US (3) US20140065113A1 (cg-RX-API-DMAC7.html)
EP (1) EP2707021B1 (cg-RX-API-DMAC7.html)
JP (5) JP2014517690A (cg-RX-API-DMAC7.html)
CN (2) CN103930439A (cg-RX-API-DMAC7.html)
AU (1) AU2012253652B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835453A1 (cg-RX-API-DMAC7.html)
IL (1) IL229316B (cg-RX-API-DMAC7.html)
WO (1) WO2012154759A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
AU2012253652B2 (en) * 2011-05-09 2017-07-06 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
IL240695B2 (en) * 2013-02-20 2024-03-01 Minerva Biotechnologies Corp Nme inhibitors and methods of using nme inhibitors
CA2963425A1 (en) * 2014-10-16 2016-04-21 Counsyl, Inc. Variant caller
IL299332A (en) 2020-06-26 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087117A (en) * 1989-10-18 2000-07-11 The United States Of America As Represented By The Department Of Health And Human Services Production and use of human nm23 protein and antibodies therefor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2005503120A (ja) * 2001-03-27 2005-02-03 マサチューセッツ　インスティテュート　オブ　テクノロジー Ｆｇｆダイマー化に関する方法及び生成物
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
AU2004252170B2 (en) * 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CN101652469B (zh) * 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
CA2729810A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
US11898160B2 (en) * 2008-10-09 2024-02-13 Minerva Biotechnologies Corporation Method for maintaining pluripotency in cells
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
US20130040845A1 (en) * 2010-02-16 2013-02-14 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP2686418A4 (en) * 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
AU2012253652B2 (en) * 2011-05-09 2017-07-06 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087117A (en) * 1989-10-18 2000-07-11 The United States Of America As Represented By The Department Of Health And Human Services Production and use of human nm23 protein and antibodies therefor

Also Published As

Publication number Publication date
WO2012154759A3 (en) 2014-05-01
EP2707021A4 (en) 2015-08-05
EP2707021B1 (en) 2024-02-21
IL229316B (en) 2020-02-27
EP2707021C0 (en) 2024-02-21
US20140065113A1 (en) 2014-03-06
IL229316A0 (en) 2014-01-30
JP2024056702A (ja) 2024-04-23
EP2707021A2 (en) 2014-03-19
CN112028985A (zh) 2020-12-04
JP2020039359A (ja) 2020-03-19
JP6717725B2 (ja) 2020-07-01
JP2017061471A (ja) 2017-03-30
WO2012154759A2 (en) 2012-11-15
US20200062812A1 (en) 2020-02-27
US20240294590A1 (en) 2024-09-05
AU2012253652A1 (en) 2013-11-28
JP2022031824A (ja) 2022-02-22
JP2014517690A (ja) 2014-07-24
CN103930439A (zh) 2014-07-16
CA2835453A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
Walker et al. Structural basis for potency differences between GDF8 and GDF11
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP5787757B2 (ja) Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質
JP6346895B2 (ja) ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質
JP6170435B2 (ja) 改変ノッチンペプチドを含む融合タンパク質及びその使用
JP6486686B2 (ja) 単鎖抗体及び他のヘテロ多量体
JP2022046544A (ja) ｓｙｎＴａｃポリペプチド及びその使用
JP2023082052A (ja) キメラ抗原受容体およびその使用
JP6809789B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP6901834B2 (ja) Ｓｉｒｐ−アルファ変異体構築物及びその使用
TWI237056B (en) Fusion protein having enhanced in vivo activity of erythropoietin
CN105377893A (zh) 三聚体抗原结合分子
JP2014240413A (ja) Ｆｇｆｒ融合タンパク質によって疾患を治療するための組成物および方法
JP2017530099A (ja) Ｗｎｔシグナリングアゴニスト分子
JP2008222711A6 (ja) Ｆｇｆｒ融合タンパク質によって疾患を治療するための組成物および方法
CN107709355A (zh) 单链cd40受体激动剂蛋白
JP2017505141A (ja) 長時間作用型インスリンおよびその使用
JP2018538356A (ja) 組織修復のための二重特異性治療用タンパク質
JP2021526835A (ja) 二機能性および三機能性融合タンパク質およびその使用
JP2015521587A (ja) ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
CN105229027A (zh) Nme抑制剂以及应用nme抑制剂的方法
CN101914161B (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
KR20200100588A (ko) 재조합 폴리펩티드에서의 조작된 o-당화 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)